Rationale for early intervention with immunomodulatory treatments

Area of Science:

• Neurology
• Immunology
• Radiology

Background:

• The McDonald diagnostic criteria enable earlier multiple sclerosis diagnosis in patients with clinically isolated syndromes.
• Early disease experience significantly impacts long-term multiple sclerosis (MS) progression.
• Axonal damage and disability accumulation occur early in MS, even within the first year.

Purpose of the Study:

• To evaluate the impact of early treatment initiation with disease-modifying drugs (DMDs) in patients with clinically isolated syndromes (CIS) and early multiple sclerosis (MS).
• To determine the correlation between early disease activity (lesions, relapses) and long-term disability in MS.
• To assess the efficacy of early DMD therapy in preventing MS conversion and reducing disability.

Main Methods:

• Review of histopathological, natural history, and longitudinal studies on MS.
• Analysis of MRI lesion load and volume changes in early MS and CIS.
• Examination of data from randomized clinical trials (RCTs) of early DMDs in CIS patients with abnormal MRI.

Main Results:

• Early MRI lesions in CIS predict conversion to clinically definite MS and long-term disability.
• The number of relapses in early MS correlates with the time to disability accumulation.
• RCTs demonstrate significant benefits of early beta-interferon therapy in CIS patients, with similar studies ongoing for glatiramer acetate.

Conclusions:

• Early diagnosis and treatment initiation are critical for improving long-term outcomes in multiple sclerosis.
• The earlier disease-modifying drugs are introduced, the better the patient's long-term prognosis and reduced disability.
• Aggressive management of early MS and CIS is warranted to mitigate irreversible neurological damage.